EBMT 2022 | Improving the speed & reliability of CAR-T manufacturing in Europe
Bernd Eschgfaeller, PhD, Novartis Pharma AG, Basel, Switzerland, talks on Novartis’ ongoing efforts in improving chimeric antigen T-cell (CAR-T) manufacturing in order to deliver CAR-T products to patients reliably and consistently. With this aim, Novartis has established multiple manufacturing facilities and over 170 treatment centers across Europe. Dr Eschgfaeller explains that Novartis has been able to deliver tisagenlecleucel (tisa-cel) to 96% of patients with a turnaround time of 25 days per patient, and in the future, Novartis is aiming to increase the number of patients treated with CAR-T whilst reducing turnaround time. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Full time employee of Novartis Pharma AG
